In recent posts, we've outlined our updated thesis around backing mission driven founders and explained…
Version One
At Version One, an investment thesis has always been more than just defining a market sector or company stage. It has been the North Star that guides and keeps us centered amidst all the noise in early-stage VC, of which there has been a lot over the past decade! Our investment philosophy is so core […]
In recent posts, we've outlined our updated thesis around backing mission driven founders and explained…
Technology changes. The startup market evolves, and so do we as VCs. Over the past…
At Version One, an investment thesis has always been more than just defining a market sector or company stage. It has been the North Star that guides and keeps us centered amidst all the noise in early-stage VC, of which there has been a lot over the past decade!
Our investment philosophy is so core to who we are as humans and as a firm that even if we didn’t have one officially written, we’d still have the same guiding framework and convictions. But distilling our beliefs into a thesis helps communicate who we are to the outside world. We also recognize that a thesis is not static – much like product lifecycles – and as such, serves as a great timeline of how we’re evolving.
Our current investment thesis, “backing mission-driven founders at the earliest stages,” was introduced back in 2020. It perfectly encapsulates our focus on backing a certain type of deeply passionate entrepreneur… and backing them at such an early stage when few people might believe in them. Pre-seed, seed, first check, inception… that’s where we believe we can provide the most value.
Those words still hold true today, but they don’t explicitly spell out something we are always looking for when evaluating an investment opportunity. And that’s timing. Investors always talk about “Why now”, and we do too (for example, see our blog post Why Now?). But the more interesting question for us is “Why not?”
Another way to ask it is “What’s possible?” We’re interested in those rare opportunities where a founder is creating a brand new category. These opportunities are fringy and emerging (some might call them crazy, weird, whacky or wild). There’s nothing obvious or inevitable about it. They’re building something the market hasn’t yet imagined and doesn’t fit neatly into an existing market category. But if they’re right, then the fringe picks up momentum and ultimately becomes a wave.
When you’re early into a large wave, there’s so much more design space for a startup and founding team. There are no natural competitors, at least early on, and you’ve got a chance to define and lead the category.
One of the easiest ways to assess market maturity is if there’s a branded category with widely accepted terminology. When AirBnB was first starting out, there was no “sharing economy.” Once a category is branded and VCs are lining up, it’s usually too late for an early-stage firm like V1 to invest.
Going forward, we’re evolving our thesis to be even more explicit about the why now and why not:
We back mission-driven founders who are early in new areas.
Looking back on our journey over the past 10+ years, we predicted a few waves right and invested early into them:
These days, the areas on our radar are a combination of “why now” and “why not”. For instance:
We don’t want to minimize how difficult (or nearly impossible) it is to create momentum, rather than ride it. Building a startup is hard enough as it is, but pioneering founders need to build on brand new technology, find new markets, and convince everyone of the market need. BUT this is exactly who we, as venture capitalists, want to back. We look forward to meeting more of these courageous and bold founders creating transformational change!
Health / Biology, Portfolio, Version One
Shifting healthcare systems from reactive to proactive care is critical – the best outcomes occur when people can take action early, before a condition becomes a diagnosis. That’s why we are excited to announce that we have led a $2.5m pre-seed round for NiaHealth and are thrilled that they are coming out of stealth and […]
We are continually refining our thesis on healthcare, from looking at clinical-grade at-home diagnostics to biotech and…
Over the past year, some of the most interesting and intellectually-stimulating pitches we heard have…